ALS non-profit, Denali aim to identify new endpoints

Neurodegenerative disease company Denali Therapeutics Inc. (South San Francisco, Calif.) partnered with the ALS Therapy Development Institute to evaluate and analyze data collected by the institute under its Precision Medicine Program to identify new clinical endpoints for amyotrophic lateral sclerosis.

The institute said new endpoints to track disease progression could shorten clinical trials or allow them to enroll fewer patients. It is collecting data from patients who complete surveys and provide ongoing disease progression data on three measures: speech recordings, accelerometers and the revised ALS functional rating scale (ALSFRS-R), a questionnaire to evaluate the pace of disease progression. ...